Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share
Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the Company's common stock, having exercise prices of $9.7665 and $32.40 per share, issued by Dermata in November 2023 (with respect to 462,945 warrants) and May 2023 (with respect to 53,391 warrants), at a reduced exercise price of $5.16 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-275931) and on Form S-1 (333-273170). The closing of the offering is expected to occur on or about May 21, 2024, subject to satisfaction of customary closing conditions.
Dermata Therapeutics, Inc.（纳斯达克股票代码：DRMA）（纳斯达克股票代码：DRMAW）（“Dermata” 或 “公司”）是一家专注于治疗医学和美容皮肤病和疾病的后期生物技术公司，今天宣布签订最终协议，立即行使某些未偿认股权证，总共购买公司普通股516,336股，行使价为9.9美元 Dermata于2023年11月（涉及462,945份认股权证）和2023年5月（涉及53,391份认股权证）发行的每股7665美元和32.40美元，发行价为每股行使价下调为5.16美元。行使认股权证时可发行的普通股根据S-3表格（文件编号333-275931）和S-1表格（333-273170）上的有效注册声明进行登记。此次发行预计将于2024年5月21日左右结束，但须满足惯例成交条件。
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
H.C. Wainwright & Co. 担任本次发行的独家配售代理。